Promomed values the trust of investors, works every day to strengthen the investment attractiveness of the company, and ensures maximum business transparency.
The pharmaceutical industry is at the peak of interest for investors. However, only a few companies in the sector are represented on the borrowings market.
Company plans for 2021-2025 provide for an increase in sales through the development and launch of new products and diversification of the current product portfolio.
In 2022, the Expert RA rating agency assigned PROMOMED DM LLC the long-term credit rating ruA-.

Information disclosure

  • Messages
  • Accounting (financial) statements
  • Issue documents
  • Other documents